Semaglutide acts primarily on GLP-1 receptors, while Tirzepatide is a dual GIP and GLP-1 receptor agonist, which may offer enhanced effects for some people
Across corticosteroids, acetaminophen, NSAIDs, and opioids, a consistent pattern emerges: Inflammation is suppressed, but tissue repair is impaired Pain signals are blocked, but nervous system sensitivity increases Symptoms are quieted, but root causes remain unaddressed Over time, this creates a widening gap between temporary symptom relief and true physiologic recovery
Pretorius E, Kell DB
Rhoden EL, Teloken C, Ting, HY et al: Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil
Months 1 to 3: the neurochemical phase As semaglutide reaches therapeutic levels and the brain adapts to altered GLP-1 signaling, changes in reward processing become more apparent
PBMs negotiate rebates with drugmakers, and these behind-the-scenes deals often determine which medication you can get regardless of what's best for patients
